Blood Can J:纳米粒子治疗多发性骨髓瘤

2012-06-18 Beyond 生物谷

近日,圣母大学的研究人员已经研制出一种纳米粒子,该粒子显示出巨大的用于治疗多发性骨髓瘤(MM)的潜力。 治疗MM的临床医生面对的困难之一就是:这种类型的癌细胞对先进的化疗治疗手段产生了耐药性。 化学和生物分子工程助理教Ba?ar Bilgi?er说:我们设计的纳米粒子有多重功效。首先,它们减少了多发性骨髓瘤对阿霉素抗药性的产生。第二,这些纳米粒子实际上可以使得癌细胞尽可能对的接触到药物

近日,圣母大学的研究人员已经研制出一种纳米粒子,该粒子显示出巨大的用于治疗多发性骨髓瘤(MM)的潜力。

治疗MM的临床医生面对的困难之一就是:这种类型的癌细胞对先进的化疗治疗手段产生了耐药性。
 
化学和生物分子工程助理教Başar Bilgiçer说:我们设计的纳米粒子有多重功效。首先,它们减少了多发性骨髓瘤对阿霉素抗药性的产生。第二,这些纳米粒子实际上可以使得癌细胞尽可能对的接触到药物纳米粒。第三,该纳米粒还可以减少药物对健康器官的毒性作用。

该纳米粒子涂有一种特殊的肽,是针对多发性骨髓瘤细胞外的特定受体。多发性骨髓瘤细胞上的特定受体可以促使细胞粘附在骨髓组织上,诱导细胞产生药物的耐药。通过使用新开发的肽,纳米粒子能够绑定到该受体,防止癌细胞粘附在骨髓。

粒子还能携带化疗药物。当一个粒子附着到MM细胞上,细胞迅速接触到纳米粒子,然后粒子释放药物,从而导致癌细胞死亡。

同时有关老鼠动物实验研究表明,阿霉素纳米粒子配方对其他组织如肾脏和肝脏的毒性大大减少。
 
这项研究刊登在Blood Cancer Journal杂志上。该研究由印第安纳临床与转化科学研究所资金支持。

doi:10.1038/bcj.2012.10
PMC:
PMID:

Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo.

T Kiziltepe, J D Ashley, J F Stefanick, Y M Qi, N J Alves, M W Handlogten, M A Suckow, R M Navari, B Bilgicer.

In the continuing search for effective cancer treatments, we report the rational engineering of a multifunctional nanoparticle that combines traditional chemotherapy with cell targeting and anti-adhesion functionalities. Very late antigen-4 (VLA-4) mediated adhesion of multiple myeloma (MM) cells to bone marrow stroma confers MM cells with cell-adhesion-mediated drug resistance (CAM-DR). In our design, we used micellar nanoparticles as dynamic self-assembling scaffolds to present VLA-4-antagonist peptides and doxorubicin (Dox) conjugates, simultaneously, to selectively target MM cells and to overcome CAM-DR. Dox was conjugated to the nanoparticles through an acid-sensitive hydrazone bond. VLA-4-antagonist peptides were conjugated via a multifaceted synthetic procedure for generating precisely controlled number of targeting functionalities. The nanoparticles were efficiently internalized by MM cells and induced cytotoxicity. Mechanistic studies revealed that nanoparticles induced DNA double-strand breaks and apoptosis in MM cells. Importantly, multifunctional nanoparticles overcame CAM-DR, and were more efficacious than Dox when MM cells were cultured on fibronectin-coated plates. Finally, in a MM xenograft model, nanoparticles preferentially homed to MM tumors with ~10 fold more drug accumulation and demonstrated dramatic tumor growth inhibition with a reduced overall systemic toxicity. Altogether, we demonstrate the disease driven engineering of a nanoparticle-based drug delivery system, enabling the model of an integrative approach in the treatment of MM.

作者:Beyond



版权声明:
本网站所有注明“来源:梅斯医学”或“来源:MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:梅斯医学”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题

相关资讯

Blood:EZH2基因或为白血病治疗新靶点

 新加坡一项研究显示,他们发现了一个3-Deazaneplanocin A(DZNep)介导细胞凋亡的新的分子机制,并提出EZH2基因可能是AML治疗的一个潜在的新靶点。研究报告2011年7月6日在线发表于《血液》(Blood)杂志。   DZNep是一种组蛋白甲基转移酶抑制剂。之前已经有几项研究表明,DZNep可破坏多梳基因抑制复合物2(PRC2),并优先在肿瘤细胞中,包括在急性髓系白血病(